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Abstract: Depression is one of the most common psychological diseases with significant 
potential morbidity and mortality. Although the underlying pathophysiology of depression has 
not been clearly defined, preclinical and clinical evidence suggest disturbances in serotonin 
(5-HT), norepinephrine (NE), and dopamine (DA) neurotransmission in the central nervous 
system. Virtually all currently available antidepressants act on one or more of the following 
mechanisms: inhibition of reuptake of 5-HT or NE (and DA), antagonism of inhibitory pre-
synaptic 5-HT or NE receptors, or inhibition of monoamine oxidase. All of these mechanisms 
result in an enhanced neurotransmission of 5-HT and/or NE. Evidence for the involvement of 
NE in depression is abundant, and recent studies on neuronal pathways and symptoms highlight 
the specific role of NE in this disorder. NE plays a determinant role in executive functioning 
regulating cognition, motivation, and intellect, which are fundamental in social relationships. 
Social dysfunction is possibly one of the most important factors affecting the quality of life in 
depressed patients.
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Introduction
Depression is associated with significant potential morbidity and mortality contributing 
to suicide, medical illness, disruption of interpersonal relationships, lost work time, 
and often leading to substance abuse.1 The underlying pathophysiology of depression 
is not clearly understood, but biological, psychological, and social factors all play a 
causal role in depression.2
Imaging studies have shown that patients with depression have smaller hippocam-
pal volume compared with controls,3 and there may be a link between depression 
and hippocampal neurogenesis.4 Evidence also suggests that major depression may 
involve an overactive hypothalamic-pituitary-adrenal axis which results in an effect 
similar to the neuroendocrine response to stress.5 The hormone, estrogen, has also 
been implicated in depressive disorders6–8 and in their treatment.9 The involvement 
of pro-inflammatory cytokines in depression is strongly suggested by meta-analyses 
of clinical studies showing higher blood concentrations of interleukin (IL)-6 and 
tumor necrosis factor (TNF)-α in depressed patients compared with controls.10,11 
Other possible disease mechanisms that have been suggested include changes in 
glutamatergic neurotransmission, reduced neurotransmission of gamma-butyric acid, 
abnormal circadian rhythms, deficient neurosteroid synthesis, impaired endogenous 
opioid function, acetylcholine imbalance, tyroxine abnormalities, and dysfunction 
of specific brain structures and circuits.12 In spite of these new hypotheses, one of Neuropsychiatric Disease and Treatment 2011:7 (Suppl 1) submit your manuscript | www.dovepress.com
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the oldest, the monoamine hypothesis which postulates a 
deficiency of serotonin (5-HT) and/or norepinephrine (NE) 
neurotransmission in the brain,13,14 is still driving clinical 
development of new antidepressants. Virtually all currently 
available antidepressants act on one or more mechanisms 
compatible with the monoamine hypothesis: inhibition 
of reuptake of 5-HT or NE; antagonism of presynaptic 
inhibitory 5-HT or NE receptors; or inhibition of monoam-
ine oxidase. All of these mechanisms result in an enhanced 
neurotransmission of 5-HT and/or NE. The confirmation of 
the clinical   activity of these antidepressants has done much 
to reinforce the monoamine hypothesis.
An association of specific features and symptoms of 
depression and a deficiency or dysfunction of certain neu-
rotransmitters has been proposed.15 Thus, a 5-HT deficiency 
is related to anxiety, obsessions, and compulsions; reduced 
NE neurotransmission is associated with decreased alertness, 
low energy, problems of inattention, concentration, and cog-
nitive ability; while dysfunctional dopamine (DA) activity is 
implicated in problems of motivation, pleasure, and reward. 
Interestingly, increased 5-HT activity can be associated with 
certain symptoms such as fatigue.16
Evidence for the involvement of 5-HT in depression has 
been the subject of numerous studies.17 The role of NE15,18 
and DA19,20 has been less extensively studied. This review 
briefly summarizes the involvement of NE in depression, 
highlighting the importance of the relationship between NE 
pathways and specific symptoms.
Evidence for the involvement  
of NE in depression
Several lines of evidence suggest that NE is a neurotransmit-
ter of major importance in the pathophysiology and treatment 
of depressive disorders.21
1.  NE projections from the locus coeruleus innervate the 
limbic system, which is implicated in the regulation of 
emotions.
2.  Numerous differences have been found in elements of the 
NE system in postmortem brains from depressed patients 
and healthy controls.
3.  Genetic studies show that mice with genetically engi-
neered functional enhancement of the NE system are pro-
tected from stress-induced depression-like behaviors.
4.  Experimental depletion of NE in the brain results in a 
return of depressive symptoms after successful treatment 
with NE antidepressant drugs.
5.  Therapeutic agents which specifically increase NE 
  activity are effective antidepressants.
NE neuroanatomy
Noradrenergic pathways in the brain arise from the cell 
  bodies in the locus coeruleus and project to different cere-
bral regions and to the spinal cord (Figure 1). In addition to 
major projections to the frontal cortex, NE neurons project 
to the limbic system, whose various components such as the 
amygdala, hippocampus, and hypothalamus are implicated 
in emotion and cognition as well as a number of functions 
modified in depressed patients such as appetite, response to 
pain, levels of pleasure, sexual satisfaction, and aggressive   
behavior.22
Imaging studies indicate that major depression is asso-
ciated with abnormal metabolism in limbic and paralimbic 
structures of the prefrontal cortex. This abnormal metabo-
lism is normalized in the amygdala and prefrontal cortex in 
patients showing a persistent antidepressant response.22
Stahl23 has suggested that it can be instructive to consider 
brain neuroanatomy in terms of specific functional centers 
(Table 1).23–26 The “emotional” and “somatic” centers in the 
brain receive projections from both NE and 5-HT as well as 
DA pathways. The “cognitive” centers, on the other hand, 
receive input only from NE as well as DA and histaminergic 
projections, but not 5-HT projections.23–26
Executive function is a complex organization of higher 
mental functions that process mental and environmental input 
to enable efficient problem-solving capacity in a way that 
is acceptable to both the individual and society. It includes 
inhibition of irrelevant or unacceptable behavior, the suppres-
sion of nonpertinent information, the regulation of verbal and 
nonverbal working memory, self-regulation of affect, motiva-
tion and arousal, planning, decision-making, self-monitoring 
of the problem-solving process, and self-evaluation of the 
results of the action taken. Anatomically, this occurs in the 
prefrontal lobe of the cortex and its afferent and efferent 
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Figure 1 Sagittal section of the human brain, showing the principal noradrenergic 
pathways. 
Adapted with permission from Moret C. Understanding neurotransmission in the brain. 
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structures involving the neurotransmitters NE and DA and 
to a lesser degree acetylcholine and 5-HT.27
Executive function is also fundamental to social   relationships. 
Social dysfunction in depression is possibly one of the most 
important factors affecting the quality of life of patients. 
  Considerable clinical data suggest the importance of NE in the 
improvement of clinical dysfunction in depression.28
Biochemical differences between 
depressed patients and healthy controls
An early study29 found increased β-adrenergic receptor bind-
ing in the frontal cortex of suicide victims. More recently, 
post-mortem and functional imaging studies in the prefrontal 
cortex of depressed suicide victims have shown altered den-
sity and sensitivity of α2A-adrenoceptors which modulate NE 
release.30–32 In addition, decreased NE transporter binding has 
been reported in locus coeruleus of postmortem samples from 
subjects diagnosed with major depression.33 Alterations in 
putative peripheral markers of central NE function, such as 
α2-adrenoceptor density in platelets, have also been found in 
depressed patients.34,35 These modifications may all be part of the 
primary causal physiopathology of depression.   Alternatively, 
at least some of them could be the result of compensatory 
modifications resulting from changes of NE neurotransmission 
in depressed patients. Whatever the interpretation, these data 
imply an important role for NE in depression.
Genetic studies of NE function
Genetic studies of NE function have indicated the mul-
tiple roles that NE plays in normal and pathological states. 
  Functional deletion (knockout) of the NE transporter in mice 
results in increased extracellular levels of NE.36 This model 
functionally mimics the therapeutic effects of selective 
NE antidepressants. Recently, this model has shown that 
NE transporter (NET) knockout mice are resistant to the 
stress-induced depressive-like changes in behavior and brain 
neurotrophin expression that are seen in wild-type mice.37 
Human genetic studies have shown that variations in the 
gene coding for NET which alter neurotransmitter release 
are related to individual differences in behavior and suscep-
tibility to depression.38 The polymorphism, NET-T182C, 
for example, is associated with an increased susceptibility 
to depression.39
Catechol-O-methyltransferase (COMT) 158Val/Met 
is a polymorphism of a major enzyme in catecholamine 
  inactivation. The alleles encoding Val and Met are associ-
ated with relatively high and relatively low COMT activity, 
  respectively. The Val/Val genotype, a high-activity COMT 
genotype, was significantly less frequent in male suicide com-
pleters than in male controls.40 An association of 158Val/Met 
polymorphism with major depression is still unclear, since some 
studies have found the Met allele (low COMT activity) to be 
associated with major depression41 while others have not.42,43
NE depletion studies
Studies in depressed patients in remission and no longer 
taking medication have shown that a drastic reduction of NE 
levels (by inhibition of the key synthetic enzyme, tyrosine 
hydroxylase, with α-methyl-p-tyrosine) results in a rapid 
reappearance of depressive symptoms. Interestingly, how-
ever, catecholamine depletion in healthy control volunteers 
does not result in depressed mood.18,44,45
Clinical activity of noradrenergic 
antidepressants
A considerable proportion of patients fail to respond ade-
quately to selective serotonin reuptake inhibitors (SSRIs). 
Analysis of the unresolved symptoms suggests that a specific 
set of symptoms related to decreased positive affect respond 
poorly to serotonergic antidepressants, namely loss of plea-
sure, loss of interest, fatigue, and loss of energy.46 There is 
evidence to suggest that antidepressants that enhance NE 
and DA activity offer a therapeutic advantage over 5-HT 
antidepressants in the treatment of symptoms associated with 
reduced positive affect.
Table 1 Neuronal projections to different brain “centers”
Emotional centers
NE projections from the locus coeruleus to the hypothalamus
NE projections from the locus coeruleus to the amygdala and  
prefrontal cortex
5-HT projections from the midbrain raphe to the hypothalamus
5-HT projections from the midbrain raphe to the amygdala and prefrontal 
cortex
DA projections from the ventral tegmentum to the nucleus accumbens
Somatic centers
NE projections from the locus coeruleus to the hypothalamus
NE projections from the locus coeruleus to the cerebellum
NE projections from the locus coeruleus to the spinal cord
5-HT projections from the midbrain raphe to the hypothalamus
5-HT projections from the midbrain raphe to the striatum
5-HT projections from the midbrain raphe to the spinal cord
DA projections from the substantia nigra to the striatum
Cognitive centers
NE projections from the locus coeruleus to the dorsolateral  
prefrontal cortex
DA projections from the ventral tegmentum to the dorsolateral 
prefrontal cortex
Histamine projections from the hypothalamus to the dorsolateral 
prefrontal cortex
Source: Summarized from references 23–26.
Abbreviations: 5-HT, serotonin; DA, dopamine; NE, norepinephrine. Neuropsychiatric Disease and Treatment 2011:7 (Suppl 1) submit your manuscript | www.dovepress.com
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The undisputed antidepressant action of NE-selective 
  tricyclic antidepressants such as desipramine and nortrip-
tyline suggests a major involvement of NE neurotransmission 
in depression, although these compounds or their metabolites 
also have some action on the 5-HT system. The selective NE 
reuptake inhibitor, reboxetine, has demonstrated equivalent 
efficacy to the TCA (tricyclic antidepressants) in some 
studies47,48 and is approved as an antidepressant in Europe 
but not in the USA. A recent publication49 suggests, however, 
that there may be considerable publication bias and that if 
unpublished studies are also considered, the antidepressant 
activity is unclear.
The SNRIs (serotonin and norepinephrine reuptake 
inhibitors) venlafaxine, milnacipran, and duloxetine show 
at least equivalent antidepressant efficacy to the SSRIs, and 
there is evidence that they may be more effective than the 
SSRIs in achieving remission.50
Conclusion
Although 5-HT has been the most studied neurotransmitter 
in depression, converging lines of evidence suggest that NE 
is of major importance in the pathophysiology and treatment 
of depressive disorder. NE projections from the locus ceo-
ruleus innervate the limbic system, which is implicated in the 
regulation of emotions and cognition. Substantial functional 
biochemical differences exist in the NE system in postmortem 
brains from depressed patients and healthy controls. Genetic 
manipulation of the NE system that increases NE neurotrans-
mission protects animals from stress-induced depressive 
behavior, while chemical manipulation that depletes the brain 
of NE increases the susceptibility of recovered depressed 
patients to a depressive relapse. Therapeutic agents which 
specifically increase NE activity are effective antidepressants, 
and there is evidence that those acting simultaneously on 
5-HT and NE neurotransmission may have an antidepressant 
action superior to SSRIs.50
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